0001209191-23-052048.txt : 20231004
0001209191-23-052048.hdr.sgml : 20231004
20231004172838
ACCESSION NUMBER: 0001209191-23-052048
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231004
DATE AS OF CHANGE: 20231004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRENDERGAST FRANKLYN G
CENTRAL INDEX KEY: 0001233256
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39580
FILM NUMBER: 231308998
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunome Inc.
CENTRAL INDEX KEY: 0001472012
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770694340
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 665 STOCKTON DRIVE
STREET 2: SUITE 300
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 610-321-3700
MAIL ADDRESS:
STREET 1: 665 STOCKTON DRIVE
STREET 2: SUITE 300
CITY: EXTON
STATE: PA
ZIP: 19341
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-02
0
0001472012
Immunome Inc.
IMNM
0001233256
PRENDERGAST FRANKLYN G
C/O IMMUNOME, INC.
665 STOCKTON DRIVE, SUITE 300
EXTON
PA
19341
1
0
0
0
0
Common Stock
2023-10-02
4
A
0
60840
0.00
A
60840
D
Stock Option (Right to Buy)
1.35
2023-10-02
4
A
0
137725
1.35
A
2032-09-26
Common Stock
137725
137725
D
In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.
In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.
/s/ Sandra Stoneman, Attorney-in-Fact
2023-10-02